

Supplemental Data

Table 1. Baseline Variables

Variables	Total (n=270)	Low MA (<35.35mm) (n=128)	High MA (≥35.35mm) (n=142)	P- value
Age (years)	57.1 ± 9.8	57.2 ± 10	57 ± 9.6	0.87
Body Mass Index (BMI) (kg/m ²)	31.6 ± 6.9	29.8 ± 6.1	33.2 ± 7.2	<0.001
Male Gender (%)	165/270 (60%)	78/128 (61%)	84/142 (59%)	0.77
African American (%)	66/270 (24%)	29/128 (22.7%)	37/142 (26.1%)	0.52
Smoking (%)	100/270 (37%)	40/128 (31.3%)	60/142 (42.3%)	0.06
Hypertension (%)	250/270 (92.6%)	118/128 (92.2%)	132/142 (93%)	0.81
Hyperlipidemia (%)	243/270 (90%)	115/128 (89.8%)	128/142 (90.1%)	0.94
Diabetes Mellitus (%)	119/270 (44.1%)	44/128 (34.4%)	75/142 (52.8%)	0.002
History of Myocardial Infarction	177/270 (65.6%)	81/128 (63.3%)	96/142 (67.6%)	0.46

History of CABG	52/270 (19.3%)	27/128 (21.1%)	25/142 (17.6%)	0.47
Congestive Heart Failure (%)	42/270 (15.6%)	16/128 (12.5%)	26/142 (18.3%)	0.19
Clinical Presentation				
STEMI	42/270 (15.6%)	19/128 (14.8%)	23/142 (16.2%)	0.76
NSTEMI	60/270 (22.2%)	22/128 (17.2%)	38/142 (26.8%)	0.06
Unstable Angina	67/270 (24.8%)	32/128 (25%)	35/142 (24.6%)	0.95
Stable CAD	97/270 (35.9%)	51/128 (39.8%)	46/142 (32.4%)	0.2
PCI vessel				
Left main	3/270 (1.1%)	2/128 (1.6%)	1/142 (0.7%)	0.5
LAD	116/270 (43%)	59/128 (46.1%)	57/142 (40.1%)	0.48
CX	65/270 (24.1%)	28/128 (21.9%)	37/142 (26.1%)	0.42
RCA	119/270 (44.1%)	56/128 (43.8%)	63/142 (44.4%)	0.92
Number of Stents Implanted	1.53 ± 0.8	1.51 ± 0.8	1.54 ± 0.8	0.74
Drug eluting stents	204/270 (75.6%)	102/128 (79.7%)	102/142 (71.8%)	0.13
Paclitaxel eluting	41/270 (15.2%)	16/128 (12.5%)	25/142 (17.6%)	0.24

stent				
Sirolimus eluting stent	14/270 (5.2%)	9/128 (7%)	5/142 (3.5%)	0.19
Zotarolimus eluting stent	9/270 (3.3%)	5/128 (3.9%)	4/142 (2.8%)	0.62
Everolimus eluting stent	138/270 (51.1%)	69/128 (53.9%)	69/142 (48.6%)	0.38
Betablockers (%)	248/270 (91.9%)	121/128 (94.5%)	127/142 (89.4%)	0.13
ACE-inhibitors/ARB (%)	190/270 (70.4%)	92/128 (71.9%)	98/142 (69%)	0.61
Calcium Channel Blockers (%)	39/270 (14.4%)	20/128 (15.6%)	19/142 (13.4%)	0.6
Statins	238/270 (88.1%)	114/128 (89.1%)	124/142 (87.3%)	0.6
Aspirin	269/270 (99.6%)	127/128 (99.3%)	142/142 (100%)	0.96
Clopidogrel	219/270 (81.1%)	110/128 (85.9%)	109/142 (76.8%)	0.054
Prasugrel	37/270 (13.7%)	13/128 (10.2%)	24/142 (16.9%)	0.11
Ticagrelor	8/270 (3%)	3/128 (2.3%)	5/142 (3.5%)	0.57

Table 1.

Baseline demographics and clinical variables for total study population, and grouped according to low and high fibrin clot strength (MA). Comparison of variables with t-test for continuous variables and chi-square for categorical variables.